tirzepatide and thyroid medication Raises Risk in Certain At-Risk Patients Tirzepatide and Thyroid Nodules: Safety
Description
Ask your doctor about anti-nausea medications if symptoms persist
Jun 30 2021;22(13)doi:10.3390/ijms22137052 Guillou S, Ghabri S, Jannot C, Gaillard E, Lamour I, Boisnic S
Just mention it
The question of whether semaglutide can be administered every other week rather than weekly is not supported by current FDA labeling or clinical trial evidence
Tirzepatide, a GLP-1 receptor agonist and GIP receptor agonist, has demonstrated weight loss outcomes of 20% or more in clinical trials when combined with lifestyle modification
Growth hormone elevation can theoretically affect insulin sensitivity
